Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03341910 · ClinicalTrials.gov registry record · Phase 2
A Study to Assess the Safety and Local Tolerability of DFD-03 (Tazarotene) Lotion, 0.1% Compared to Tazorac® Cream, 0.1% in the Topical Treatment of Acne Vulgaris
A Phase 2 study, sponsored by Dr. Reddy's Laboratories Limited.
- Completed
- Registry status
- Phase 2
- Development phase
- 155
- Enrollment target
NCT03341910 is a Phase 2 study that has completed, run by Dr. Reddy's Laboratories Limited. The registered enrollment target is 155 participants.
The verdict
NCT03341910, a Phase 2 study, has completed, sponsored by Dr. Reddy's Laboratories Limited.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 155 participants
- Enrollment target
Study Summary
A study for Subjects with mild to moderate facial acne vulgaris. During the 12-week treatment period subjects randomized to DFD-03 Lotion or Vehicle Lotion will use the study drug twice daily. Subjects randomized to Tazorac Cream or Vehicle Cream will use the study drug once daily in the evening. Safety assessments will include the investigator's assessment of local cutaneous tolerance/application site reactions on the face, vital signs and adverse events.
Interventions
- DRUG Tazorac Cream, 0.1%
- DRUG DFD-03 Lotion, 0.1%
- DRUG DFD-03 Vehicle Lotion 0%
- DRUG Tazorac Vehicle Cream 0%
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 155 participants |
| Start Date | 2017-08-21 |
| Est. Completion | 2018-05-18 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03341910
The ClinicalTrials.gov registry entry for NCT03341910 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 155 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Dr. Reddy's Laboratories Limited, which has 52 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Tazorac Cream, 0.1% is the first listed.
NCT03341910 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03341910 about?
NCT03341910 is a clinical study titled "A Study to Assess the Safety and Local Tolerability of DFD-03 (Tazarotene) Lotion, 0.1% Compared to Tazorac® Cream, 0.1% in the Topical Treatment of Acne Vulgaris". A study for Subjects with mild to moderate facial acne vulgaris. During the 12-week treatment period subjects randomized to DFD-03 Lotion or Vehicle Lotion will use the study drug twice daily. Subjects randomized to Tazorac Cream or Vehicle Cream will use the study drug once daily in the evening. Sa...
What is the current status of trial NCT03341910?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 155 participants. The study started on 2017-08-21. Estimated completion is 2018-05-18.
What interventions are being tested in trial NCT03341910?
The interventions under investigation include: Tazorac Cream, 0.1% (DRUG), DFD-03 Lotion, 0.1% (DRUG), DFD-03 Vehicle Lotion 0% (DRUG), Tazorac Vehicle Cream 0% (DRUG).
Who is sponsoring clinical trial NCT03341910?
This trial is sponsored by Dr. Reddy's Laboratories Limited, which has 52 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.